首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1741101

循环肿瘤cfDNA（游离DNA）市场按肿瘤类型、癌症类型、技术、应用和地区划分

Circulating Cell-Free Tumor DNA Market, by Tumor Type, by Cancer Type by Technology, by Application, and by Region

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

简介目录

循环肿瘤cfDNA（游离DNA）市场规模预计在2025年为92.2亿美元，预计到2032年将达到390.5亿美元，2025年至2032年的年复合成长率（CAGR）为22.9%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	92.2亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	22.90%	2032年价值预测	390.5亿美元

循环肿瘤DNA (ctDNA) 是指在血液中循环的恶性细胞或肿瘤的DNA。细胞核包含其大部分DNA。随着肿瘤的扩大，细胞会死亡并被新细胞取代。被破坏的死细胞会将其内容物（包括DNA）排放到血液中。 ctDNA是一小段DNA，通常长度少于200个碱基。 ctDNA的数量因人而异，并受肿瘤类型、位置以及恶性肿瘤分期的影响。循环肿瘤DNA (ctDNA) 通常包含可用于癌症检测的基因变异。 ctDNA的其他重要应用包括预后、治疗监测和肿瘤体积估计。如果新的癌症检测方法能够在治癒率最高的早期、无症状阶段检测出癌症，其临床效用将达到最大程度。循环肿瘤DNA分析有助于早期发现癌症，并可用于提供分子标靶治疗。

市场动态

主要企业越来越多地采用产品发布等内部成长策略来扩大产品系列，预计这将在预测期内推动市场成长。例如，下一代分子诊断公司 BillionToOne Inc. 宣布于 2022 年 7 月推出首款肿瘤液态切片产品 Northstar Select 和 Northstar Response。这些产品目前可供部分学术癌症中心进行研究。 Northstar Select 是全面的泛癌症体细胞突变分析面板。利用 BillionToOne 专有的分子计数技术，即定量计数模板 (QCT)，该面板在识别可操作突变方面实现了显着的检测极限。同时，Northstar Response 是一种基于甲基化的组织诊断治疗反应监测试验。

本研究的主要特点

本报告对全球循环肿瘤cfDNA（游离DNA）市场进行了详细分析，并提供了预测期2025-2032的市场规模和年复合成长率（CAGR%），假设2024年为基准年。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
它根据公司亮点、产品系列、关键亮点、绩效和策略等参数，介绍了全球循环肿瘤 cfDNA（无细胞 DNA）市场的主要企业概况。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
这份全球循环肿瘤cfDNA（游离DNA）分析报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球细胞吸收肿瘤 DNA 市场的各种策略矩阵来更轻鬆地做出决策。

Biocept, Inc.
Illumina, Inc.
Quest Diagnostics Incorporated
KURABO INDUSTRIES LTD
PerkinElmer chemagen Technologie GmbH
Biodesix
Guardant Health
QIAGEN
Sequenom, Inc.
Agilent Technologies, Inc.
Fluxion Biosciences Inc.
Natera, Inc.
Agena Bioscience, Inc.
Paragon Genomics, Inc.
Lucence Health Inc.
Eurofins Genomics
Thermo Fisher Scientific

第 11 章章节

调查方法
关于出版商

简介目录

Product Code: CMI5819

Circulating Cell-Free Tumor DNA Market is estimated to be valued at USD 9.22 Bn in 2025 and is expected to reach USD 39.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 9.22 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	22.90%	2032 Value Projection:	USD 39.05 Bn

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne's proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:
- Malignant Tumors
- Precancerous Tumors
Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Global Circulating Cell-Free Tumor DNA Market, By Technology:
- PCR
- Massively Parallel Sequencing
- Single Nucleotide Polymorphism
Global Circulating Cell-Free Tumor DNA Market, By Application:
- Cancer Diagnosis
- Targeting Therapeutics
- Prognosis Indication
Global Circulating Cell-Free Tumor DNA Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Biocept, Inc.
- Illumina, Inc.
- Quest Diagnostics Incorporated
- KURABO INDUSTRIES LTD
- PerkinElmer chemagen Technologie GmbH
- Biodesix
- Guardant Health
- QIAGEN
- Sequenom, Inc.
- Agilent Technologies, Inc.
- Fluxion Biosciences Inc.
- Natera, Inc.
- Agena Bioscience, Inc.
- Paragon Genomics, Inc.
- Lucence Health Inc.
- Eurofins Genomics
- Thermo Fisher Scientific

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Tumor Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Circulating Cell-free Tumor DNA Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Malignant Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Precancerous Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segments Trends
PCR
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Massively Parallel Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Single Nucleotide Polymorphism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Global Circulating Cell-free Tumor DNA Market, By Application, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cancer Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Targeting Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
Prognosis Indication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

9. Global Circulating Cell-free Tumor DNA Market, By Region, 2020 - 2032, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Biocept, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Illumina, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Quest Diagnostics Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
KURABO INDUSTRIES LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PerkinElmer chemagen Technologie GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biodesix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Guardant Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
QIAGEN
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sequenom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agilent Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Fluxion Biosciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Natera, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Agena Bioscience, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Paragon Genomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lucence Health Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eurofins Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

11. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

循环肿瘤cfDNA（游离DNA）市场按肿瘤类型、癌症类型、技术、应用和地区划分